Clinical Trials

Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (CTMS# 18-0005)

Cancer Type

Other Hematopoietic

ClinicalTrials.gov Identifier

NCT02953704

Principal Investigator

Ruben Mesa M.D.

For more information about this study
View Details

About This Study

The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).